Aller au contenu principal

Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse

Les 20 dernières publications

Titre Auteurs Date de publication Source
De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells Olivia Bawa, Jean Yves Scoazec 01/12/2022 Molecular Cancer
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test Damien Vasseur, Etienne Rouleau, Ludovic Lacroix 01/06/2022 Cells
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies Ludovic Lacroix, Sophie Cotteret, Jean Yves Scoazec 01/05/2022 Cancer Discovery
Cancer stem-like cells evade CD8<sup>+</sup>CD103<sup>+</sup> tumor-resident memory T (T<inf>RM</inf>) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model Aziza Caidi, Marc Deloger 13/04/2022 Journal for ImmunoTherapy of Cancer
Therapeutic potential of the human endogenous retroviral envelope protein HEMO: a pan-cancer analysis Olivia Bawa, Bastien Job, Jean Yves Scoazec 01/04/2022 Molecular Oncology
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients Damien Vasseur, Ludovic Lacroix, Jean Yves Scoazec 01/04/2022 Annals of Oncology
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial Marie Naigeon, Lydie Cassard, Lisa Boselli, Jonathan Grivel, Ludovic Lacroix, Nathalie Chaput 01/04/2022 Lung Cancer
TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy Nicolas Signolle 17/03/2022 Journal for ImmunoTherapy of Cancer
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy Jean Yves Scoazec 14/03/2022 Cancer Cell
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers Boris Duchemann, Marie Naigeon, Lydie Cassard, Jean Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Nathalie Chaput 07/02/2022 Journal for ImmunoTherapy of Cancer
Diagnostic accuracy of in vivo early tumor imaging from probe-based confocal laser endomicroscopy versus histologic examination in head and neck squamous cell carcinoma Muriel Abbaci, Frederic De Leeuw, Corinne Laplace-Builhe 01/02/2022 Clinical Oral Investigations
Adoptive cell therapies in thoracic malignancies Marie Naigeon, Nathalie Chaput, Boris Duchemann 01/01/2022 Cancer Immunology, Immunotherapy
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer Damien Vasseur, Cécile Jovelet, Etienne Rouleau, Ludovic Lacroix 01/01/2022 Clinical Lung Cancer
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients Virginie Marty 01/01/2022 OncoImmunology
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade Nathalie Chaput 15/12/2021 Clinical Cancer Research
Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms Cyril Catelain, Philippe Rameau 02/12/2021 Blood
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation Kadija Diop, Nathalie Droin 01/12/2021 European Journal of Cancer
Serial transplantation unmasks galectin-9 contribution to tumor immune escape in the MB49 murine model Olivia Bawa, Nicolas Signolle, M’boyba K. Diop, Philippe Dessen 01/12/2021 Scientific Reports
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance Nathalie Chaput 01/11/2021 Annals of Oncology
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial Ludovic Lacroix 01/11/2021 European Journal of Cancer

Nombre de publications du laboratoire par domaine scientifique (2016-2021)

Chaque publication du laboratoire peut être rangée dans une ou plusieurs disciplines scientifiques : la figure ci-dessus présente le nombre de publications du laboratoire pour chaque discipline de la classification ASJC (Elsevier)